Effects of implementing universal and rapid HIV treatment on initiation of antiretroviral therapy and retention in care in Zambia: a natural experiment using regression discontinuity [0.03%]
在赞比亚，通过回归不连续性自然实验分析实施普遍和快速的艾滋病治疗对开始抗逆转录病毒治疗及留在护理中产生的影响
Aaloke Mody,Izukanji Sikazwe,Angella Sandra Namwase et al.
Aaloke Mody et al.
Background: Universal testing and treatment (UTT) for all people living with HIV has only been assessed under experimental conditions in cluster-randomised trials. The public health effectiveness of UTT policies on the HI...
Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study [0.03%]
在HIV-1感染成人中开始长效卡博特格拉韦联合利匹维林的治疗：开放标签三期FLAIR研究的第124周结果，直接注射给药或口服 lead-in 给药
Chloe Orkin,Enrique Bernal Morell,Darrell H S Tan et al.
Chloe Orkin et al.
Background: Previous work established non-inferiority of switching participants who were virologically suppressed from daily oral standard of care to monthly long-acting intramuscular injections of cabotegravir plus rilpi...
Randomized Controlled Trial
The lancet. HIV. 2021 Nov;8(11):e668-e678. DOI:10.1016/S2352-3018(21)00184-3 2021
Associations between HIV infection and clinical spectrum of COVID-19: a population level analysis based on US National COVID Cohort Collaborative (N3C) data [0.03%]
HIV感染与COVID-19临床谱系之间的关联：基于美国国家COVID队列协作(N3C)数据的群体水平分析
Xueying Yang,Jing Sun,Rena C Patel et al.
Xueying Yang et al.
Background: Evidence of whether people living with HIV are at elevated risk of adverse COVID-19 outcomes is inconclusive. We aimed to investigate this association using the population-based National COVID Cohort Collabora...
Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study [0.03%]
与HIV感染者SARS-CoV-2诊断和严重COVID-19结局相关的社会人口统计学、临床和免疫因素：回顾性队列研究
Daniel K Nomah,Juliana Reyes-Urueña,Yesika Díaz et al.
Daniel K Nomah et al.
Background: Factors affecting outcomes of SARS-CoV-2 infection in people living with HIV are unclear. We assessed the factors associated with SARS-CoV-2 diagnosis and severe outcomes among people living with HIV. ...
Marta Boffito,Laura Waters
Marta Boffito
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study [0.03%]
在感染HIV-1的成人中每2个月用药一次的长效卡博特格拉韦和利匹维林(ATLAS-2M)96周的结果：一项随机、多中心、开放标签、3b期非劣性研究
Hans Jaeger,Edgar T Overton,Gary Richmond et al.
Hans Jaeger et al.
Background: Long-acting cabotegravir and rilpivirine administered monthly or every 2 months might address the challenges associated with daily oral antiretroviral therapy. The ATLAS-2M week 48 results showed non-inferiori...
Clinical Trial
The lancet. HIV. 2021 Nov;8(11):e679-e689. DOI:10.1016/S2352-3018(21)00185-5 2021
Global, regional, and national sex-specific burden and control of the HIV epidemic, 1990-2019, for 204 countries and territories: the Global Burden of Diseases Study 2019 [0.03%]
1990年至2019年，全球204个国家和地区艾滋病毒流行病的性别特异性负担和控制：2019年全球疾病负担研究
GBD HIV Collaborators
GBD HIV Collaborators
Background: The sustainable development goals (SDGs) aim to end HIV/AIDS as a public health threat by 2030. Understanding the current state of the HIV epidemic and its change over time is essential to this effort. This st...
Kathryn A Risher;ALPHA Network
Kathryn A Risher;ALPHA Network
Joel Negin,Janet Seeley
Joel Negin
The Lancet Hiv
The Lancet Hiv